

# Supplemental Appendix

## Table of Contents

<b>Supplementary Methods .....</b>	<b>2</b>
<b>The details of ancillary drugs .....</b>	<b>2</b>
<b>Supplementary Tables .....</b>	<b>3</b>
<b>Supplementary Table S1. Group statistics of primary and secondary outcomes. ....</b>	<b>3</b>
Supplementary Table S1-1. Comparison of clinical recovery rate of Day 7.....	3
Supplementary Table S1-2. Comparison of duration of fever.....	4
Supplementary Table S1-3. Comparison of duration of cough relief time.....	5
Supplementary Table S1-4. Comparison of AOT or NMV. ....	6
Supplementary Table S1-5. Comparison of other secondary outcomes.....	7
<b>Supplementary Table S2. Comparison of the COVID-19 patients in combination with the     drugs. ....</b>	<b>8</b>
<b>Supplementary Figures .....</b>	<b>9</b>
<b>Supplementary Figure S1. Categorial and continuous clinical feature distribution of all FAS     patients.....</b>	<b>9</b>
<b>Supplementary Figure S2. Swimmer’s plot of clinical manifestation for all FAS patients.....</b>	<b>11</b>
<b>Supplementary Figure S3. Ancillary drug usage for all FAS patients.....</b>	<b>13</b>

## **Supplementary Methods**

### **The details of ancillary drugs**

Details of ancillary drug use were listed in Table S2 and Figure S3. Most frequently used ancillary treatments were: Moxifloxacin Hydrochloride Tablets (22/18, Favipiravir/Arbidol group); Cephalosporins (11/5); Antiviral drugs other than the experimental drugs (11/27); Glucocorticoid (5/10); and Human Serum Albumin (4/5). Besides above-mentioned medicine, Chinese herbal medicine was widely used among the patients: Lianhua Qingwen Capsule (a prespecified Chinese herbal medicine recipe for respiratory contagious diseases, 23/30); Qiangli Pipa Lu (a syrup for cough relief, 12/15); and Xuebijing Injection (a prespecified Chinese herbal medicine recipe for anti-inflammation, 8/10). We found that whilst additional antiviral treatments were more frequent in the Arbidol group ( $P=0.0045$ ), it did not positively contribute to the clinical recovery rate at Day 7. Ancillary treatments differ between moderate and severe/critical patients.

## Supplementary Tables

### Supplementary Table S1. Group statistics of primary and secondary outcomes.

#### Supplementary Table S1-1. Comparison of clinical recovery rate of Day 7.

Variables	FAS		PPS	
	Favipiravir group	Arbidol group	Favipiravir group	Arbidol group
<b>Total patients</b>	<b>N = 116</b>	<b>N = 120</b>	<b>N = 116</b>	<b>N = 115</b>
<b>Recovered, n (%)</b>	71(61.21)	62 (51.67)	71 (61.21)	58 (50.43)
<b>P value</b>	0.1396		0.0992	
<b>Rate ratio (95% CI)</b>	0.0954 (-0.0305, 0.2213)		0.1077 (-0.0196, 0.2351)	
<b>Moderate patients</b>	<b>N = 98</b>	<b>N = 111</b>	<b>N = 98</b>	<b>N = 111</b>
<b>Recovered, n (%)</b>	70 (71.43)	62 (55.86)	70 (71.43)	58 (54.72)
<b>P value</b>	0.0199		0.0136	
<b>Rate ratio (95% CI)</b>	0.1557 (0.0271, 0.2843)		0.1671 (0.0368, 0.2974)	
<b>Severe or critical patients</b>	<b>N = 18</b>	<b>N = 9</b>	<b>N = 18</b>	<b>N = 9</b>
<b>Recovered, n (%)</b>	1 (5.56)	0 (0.00)	1 (5.56)	0 (0.00)
<b>P value</b>	0.4712		0.4712	
<b>Rate ratio (95% CI)</b>	0.0556 (-0.0503, 0.1614)		0.0556 (-0.0503, 0.1614)	

**Supplementary Table S1-2. Comparison of duration of fever.**

Time	FAS		PPS	
	Favipiravir	Arbidol	Favipiravir	Arbidol
<b>Moderate patients</b>	<b>(N = 57)</b>	<b>(N = 65)</b>	<b>(N = 57)</b>	<b>(N = 62)</b>
Day 1	12 (21.05)	2 (3.08)	12 (21.05)	2 (3.23)
Day 2	23 (40.35)	8 (12.31)	23 (40.35)	8 (12.90)
Day 3	16 (28.07)	16 (24.62)	16 (28.07)	13 (20.97)
Day 4	4 (7.02)	15 (23.08)	4 (7.02)	15 (24.19)
Day 5	0 (0.00)	13 (20.00)	0 (0.00)	13 (20.97)
Day 6	0 (0.00)	4(6.15)	0 (0.00)	4 (6.45)
Day 7	0 (0.00)	2(3.08)	0 (0.00)	2 (3.23)
Day 8	-	-	-	-
Day 9	-	-	-	-
Censored	2 (3.51)	5(7.69)	2 (3.51)	5 (8.06)
<b>Log-rank P value</b>	< 0.0001		< 0.0001	

**Supplementary Table S1-3. Comparison of duration of cough relief time.**

Time	FAS		PPS	
	Favipiravir	Arbidol	Favipiravir	Arbidol
<b>Moderate patients</b>	<b>N = 60</b>	<b>N = 64</b>	<b>N = 60</b>	<b>N = 62</b>
Day 1	1 (1.67)	3 (4.69)	1 (1.67)	3 (4.84)
Day 2	1 (1.67)	1 (1.56)	1 (1.67)	1 (1.61)
Day 3	21 (35.00)	7 (10.94)	21 (35.00)	7 (11.29)
Day 4	18 (30.00)	11 (17.19)	18 (30.00)	11 (17.74)
Day 5	9 (15.00)	12 (18.75)	9 (15.00)	11 (17.74)
Day 6	7 (11.67)	10 (15.63)	7 (11.67)	10 (16.13)
Day 7	2 (3.33)	3 (4.69)	2 (3.33)	3 (4.84)
Day 8	1 (1.67)	4 (6.25)	1 (1.67)	4 (6.45)
Day 9	0 (0.00)	1 (1.56)	0 (0.00)	1 (1.61)
Censored	0 (0.00)	12 (18.75)	0 (0.00)	11 (17.74)
<b>Log-rank P value</b>	< 0.0001		< 0.0001	

**Supplementary Table S1-4. Comparison of AOT or NMV.**

Variables	FAS		PPS	
	Favipiravir	Arbidol	Favipiravir	Arbidol
<b>Total patients</b>	<b>N = 116</b>	<b>N = 120</b>	<b>N = 116</b>	<b>N = 115</b>
AOT or NMV, n (%)	21 (18.10)	27 (22.50)	21 (18.10)	26 (22.61)
<b>P value</b>	0.4015		0.3951	
<b>Rate ratio (95% CI)</b>	-0.0440 (-0.1464, 0.0585)		-0.0451(-0.1488, 0.0587)	
<b>Moderate patients</b>	<b>N = 98</b>	<b>N = 111</b>	<b>N = 98</b>	<b>N = 111</b>
AOT or NMV, n (%)	8 (8.16)	19 (17.12)	8 (8.16)	18 (16.98)
<b>P value</b>	0.0541		0.0592	
<b>Rate ratio (95% CI)</b>	-0.0895 (-0.1781, -0.0009)		-0.0882 (-0.1779, 0.0015)	
<b>Severe or critical patients</b>	<b>N = 18</b>	<b>N = 9</b>	<b>N = 18</b>	<b>N = 9</b>
NMV, n (%)	13 (72.22)	8 (88.89)	13 (72.22)	8 (88.89)
<b>P value</b>	0.3261		0.3261	
<b>Rate ratio (95% CI)</b>	-0.1667 (-0.4582, 0.1248)		-0.1667 (-0.4582, 0.1248)	
<b>Patients with hypertension and/or diabetes</b>	<b>N = 43</b>	<b>N = 35</b>	<b>N = 42</b>	<b>N = 33</b>
NMV, n (%)	9 (21.43)	10 (28.57)	9 (21.43)	10 (30.30)
<b>P value</b>	0.4691		0.3804	
<b>Rate ratio (95% CI)</b>	-0.0714 (-0.2658, 0.1230)		-0.0887 (-0.2887, 0.1112)	

**Supplementary Table S1-5. Comparison of other secondary outcomes.**

<b>Variables</b>	<b>Favipiravir group (N = 116)</b>	<b>Arbidol group (N = 120)</b>
<b>All cause mortality, n (%)</b>	0 (0.00)	0 (0.00)
Statistics	/	/
P value	/	/
<b>Respiratory failure, n (%)</b>	1 (0.86)	4 (3.33)
Statistics	-	-
P value	0.3700*	0.3700*
<b>Dyspnea, n (%)</b>	13 (11.21)	15 (12.50)
Statistics	0.0943	0.0943
P value	0.7588	0.7588
<b>Entering ICU, n (%)</b>	2 (1.72)	2 (1.67)
Statistics	-	-
P value	1.0000*	1.0000*

\*Fisher's exact test was used for comparison between groups.

**Supplementary Table S2. Comparison of the COVID-19 patients in combination with the drugs.**

<b>Combined drugs<sup>#</sup></b>	<b>Favipiravir group</b>	<b>Arbidol group</b>	<b>P value</b>
<b>Moderate patients</b>	N = 98	N = 111	
Total	81 (82.65)	93 (83.78)	0.8271
Antibiotic	21 (21.43)	20 (18.02)	0.5355
Antiviral drugs	8 (8.16)	25 (22.52)	0.0045
Glucocorticoid	2 (2.04)	8 (7.21)	0.1078
Chinese herbal medicine	74 (75.51)	85 (76.58)	0.8569
Psychotropic substances	10 (10.20)	22 (19.82)	0.0540
Immunomodulator	5 (5.10)	15 (13.51)	0.0391
Nutritional support	17 (17.35)	11 (9.91)	0.1152
<b>Severe or critical patients</b>	N = 18	N = 9	
Total	17 (94.44)	8 (88.89)	1.0000*
Antibiotic	13 (72.22)	3 (33.33)	1.0000*
Antiviral drugs	3 (16.67)	2 (22.22)	1.0000*
Glucocorticoid	3 (16.67)	2 (22.22)	1.0000*
Chinese herbal medicine	15 (83.33)	7 (77.78)	1.0000*
Psychotropic substances	4 (22.22)	4 (44.44)	0.3748
Immunomodulator	3 (16.67)	1 (11.11)	1.0000*
Nutritional support	3 (16.67)	1 (11.11)	1.0000*

\*Fisher's exact test was used for comparison between groups.

<sup>#</sup>Combined drugs:

Antibiotic: Moxifloxacin Hydrochloride Tablets, Cephalosporins

Antiviral drugs: Ribavirin Injection, Chloroquine Phosphate, Recombinant Human Interferon

Chinese herbal medicine: Lianhua Qingwen Capsule, Qiangli Pipa Lu, Xuebijing Injection


Psychotropic substances: Estazolam Tablets, Alprazolam Tablets, Dexmedetomidine, Diazepam

Immunity enhancing drugs: Human Serum Albumin (HSA), Thymalfasin

Nutritional support: Intacted Protein Enteral Nutrition, Vitamin C/B6/B12/Multivitamin




## Supplementary Figures



**Supplementary Figure S1. Categorical and continuous clinical feature distribution of all FAS patients.**

X and Y axis of this combinatorial figure was collected clinical features for all FAS patients. For continuous variable x categorical variable combinations, the distribution histogram of individuals was shown for each categorical variable. For categorical variable x continuous variable combinations, a boxplot was shown for the continuous variable in groups of categories. For categorical variable x categorical variable combinations, square area denotes the

number of patients with such combination. Feature names: Group: case is the favipiravir group and control is the arbidol group. PCR baseline: N is negative and P is positive for SARS-CoV-2. Classification: clinical classification of moderate, severe and critical patients. DB: diabetes. HT: hypertension. DBHT: diabetes and/or hypertension. Cough Relief Class: Y is relieved, N is not relieved, and NoSyndrome means not coughing at the time of enrollment. Fever Relief Class: Y is relieved, N is not relieved, and NoSyndrome means no fever at the time of enrollment. Recovery at Day 7: the primary outcome, where Y is positive and N is negative. Analysis and plot were done by GGally (1.4.0) package in R (3.6.2).



Supplementary Figure S2. Swimmer's plot of clinical manifestation for all FAS patients.

X axis denotes the days beginning from first dosing, and patients were distributed on Y axis. Each lane denotes a patient, where the swimming lane length denotes in-hospital observation time. Clinical classification of each patient was colored in the lane as white (moderate), gray (severe) or black (critical). Discharge events were denoted as green circle (usually at the end of lane). Continuous in-hospitalization were denoted as red arrowhead at the end of lane. Fever relief events were denoted as red triangle. Cough relief events were denoted as yellow triangle. PCR tests for SARS-CoV-2 were performed at Day 0 (before enrollment, on the left of each lane), Day 3 and Day 7, where a red “P” denotes positive result and a green “N” denotes negative result. The primary endpoint, recovery of syndromes at Day 7, was denoted at the rightmost of the panel as red (recovered, a positive outcome) or blue (not recovered, a negative outcome) rhombics. Analysis and plot were done by R (3.6.2).

